Ekamol Tantisattamo, MD
Nephrology · Orange, CANPI 1104053024
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,573 of the $3,043 with a category attached, or 84.6%. Astrazeneca UK Limited accounts for 84.6% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $2,685, more than ten times the $14 reported in 2019.
Across 10 payments — averaging $304.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$3K
- AstraZeneca$243
- Sanofi$100
- Veloxis Pharmaceuticals, Inc.$54
- Calliditas Therapeutics US Inc.$39
- Novo Nordisk$21
- plus $14 from 1 others
Across 7 payments — averaging $20,386 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$67K
- AstraZeneca$66K
- Recor Medical Inc$10K
What the payments were for
- Consulting fees$2,57385%
- Travel & lodging$1555%
- Food & beverage$2478%
- Education$682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 1 | $2,573 |
| AstraZeneca | 3 | $243 |
| Sanofi | 1 | $100 |
| Veloxis Pharmaceuticals, Inc. | 1 | $54 |
| Calliditas Therapeutics US Inc. | 2 | $39 |
| Novo Nordisk | 1 | $21 |
| Fresenius USA Marketing, Inc. | 1 | $14 |
How this compares
$3,043 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $14,869 |
| Valganciclovir Hcl | 32 | $6,770 |
| EntrestoSacubitril/Valsartan | 12 | $3,941 |
| Nifedipine ErNifedipine | 83 | $2,752 |
| Nebivolol Hcl | 12 | $1,042 |
| Carvedilol | 109 | $667 |
| Hydralazine Hcl | 34 | $455 |
| Bumetanide | 11 | $409 |
| Losartan Potassium | 123 | $354 |
| Amlodipine Besylate | 49 | $324 |
| Minoxidil | 12 | $311 |
| Metoprolol Succinate | 20 | $282 |
| Spironolactone | 16 | $217 |
| Tamsulosin Hcl | 22 | $167 |
| Prednisone | 47 | $142 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Orange
- Yasir QaziOrange$618K
- Ramy HannaOrange$446K
- Kamyar KalantarOrange$421K
- Rebecca AhdootOrange$66K
- Yongen ChangOrange$48K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.